

**THERMOGENESIS HIRES NEW EXECUTIVE
DIRECTOR OF SCIENTIFIC AFFAIRS**

Rancho Cordova, California (June 8, 2005) -- THERMOGENESIS CORP. (Nasdaq: KOOL) announced today that it has hired John R. Chapman, Ph.D. as its Executive Director of Scientific Affairs.

Dr. Chapman is an internationally published scientist in the field of blood systems development and pathogen inactivation of blood components and has obtained 24 issued U.S. Patents and authored 32 scientific publications in the fields of blood processing, biologics, devices and chemistry. Most recently, he held the position of Sr. Vice President of Research and Development (R&D) at V.I.Technologies (Vitex). At Vitex, he successfully authored a Phase I/II SBIR fast track grant totaling \$1 million for development of a blood purification system and led the multidisciplinary R&D team from drug discovery to Phase III clinical trials.

Prior to joining Vitex, he had 16 years of experience working for Baxter Healthcare in the divisions of Applied Sciences and Transfusion Therapies (Fenwal) including two years as an expatriate in Brussels, Belgium. At Baxter, he provided the scientific leadership in creating the CE mark and market launch of a new pathogen inactivation system of fresh frozen plasma using photoactivation of methylene blue.

Dr. Chapman commented, "I am very excited to have the opportunity of joining the ThermoGenesis team and look forward to effectively contributing to the development, launch and promotion of its life saving medical device products for stem cell therapy and surgical hemostasis. It is stimulating to join a company with product platforms that are both medically and commercially significant and position the company for strong growth in the near term."

Kevin Simpson, President & COO, noted that "Dr. Chapman brings a wealth of scientific knowledge and blood experience to the ThermoGenesis team. Dr. Chapman will be responsible for coordinating the life science and clinical activities with the R&D, clinical affairs, global medical and marketing teams, and field sales and service to facilitate the successful development, launch and promotion of new and existing medical device products. We are fortunate to have John join our management team and look forward to benefiting from his scientific expertise and his seasoned leadership in blood product development."

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

###

More Information, Contact:
THERMOGENESIS CORP.
Kevin Simpson: (916) 858-5100